Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bioxcel Therapeutics Inc (NQ: BTAI )

32.01 +0.88 (+2.83%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 363,377
Open 31.63
Bid (Size) 31.40 (2)
Ask (Size) 31.95 (6)
Prev. Close 31.13
Today's Range 31.36 - 32.78
52wk Range 8.795 - 32.96
Shares Outstanding 28,023,225
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
Why BioXCel Therapeutics Stock Jumped This Week
A couple of analysts recently upgraded their views on the biotech stock. 
Via The Motley Fool

Performance

YTD
+49.16%
+49.16%
1 Month
+47.17%
+47.17%
3 Month
+168.09%
+168.09%
6 Month
+103.76%
+103.76%
1 Year
+94.83%
+94.83%

More News

Read More
2 Beaten-Down Stocks to Watch Closely Next Year
Via The Motley Fool
Why BioXcel Therapeutics Stock Triumphed This Week
Via The Motley Fool
Analyst Ratings for BioXcel Therapeutics
Via Benzinga
Is This Soaring Growth Stock a Buy?
Via The Motley Fool
Recap: BioXcel Therapeutics Q2 Earnings
Via Benzinga
BioXcel Therapeutics: Q1 Earnings Insights
Via Benzinga
Oaktree, Qatar Investment Inject $260M In BioXcel To Fund Commercialization Of Schizophrenia Med
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
Via Benzinga
Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher'
Via Benzinga
24 Stocks Moving in Thursday's Pre-Market Session
Via Benzinga
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Via Benzinga
Twitter Shares Surge Around 8%, Here's 66 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
Via Benzinga
Preview: BioXcel Therapeutics's Earnings
Via Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
Via Benzinga
How To Attend BioXcel Therapeutics Q1 2022 Earnings Conference Call
Via Benzinga
The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu
Via Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Via Benzinga
Looking Into Bioxcel Therapeutics Inc's Recent Short Interest
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For April 7, 2022: SDPR S&P 500, Houghton Mifflin, Sunshine Biopharma And More
Via Benzinga
4 Top Stock Trades for Thursday: MSFT, TWTR, BTAI, PXD
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.